June 2020, Moscow: When a person is diagnosed with cancer, they immediately start looking for information about their diagnosis. However, it is easy to get lost in the heaps of information out there. Furthermore, not all of this information can be useful, and in fact, some may even be harmful. That is why the US non-profit alliance, the NCCN or National Comprehensive Cancer Network, is releasing patient guidelines on treating certain types of diseases. At the moment, this is the most reliable and authoritative source of information.
The guideline on multiple myeloma, translated by the Leukemia Foundation in collaboration with the Doctor Laskov’s Oncological Clinic and supported by the company Janssen Russia, a pharmaceutical product sub-division of Johnson & Johnson LLC, is the first guideline on oncohematological diseases available in Russian. It is designed to help people get a better understanding of the disease with which they have been diagnosed and how to treat it. The guideline on multiple myeloma contains useful information on treatment options that can have the maximum impact. It is based on treatment protocols that are used all over the world. How is the diagnosis made? What are the initial symptoms? How is treatment determined? What kind of monitoring is required during treatment? People diagnosed with multiple myeloma can find the answers to all of these questions in the guideline. This will help them when discussing their diagnosis with their attending physician.
You can download the guideline using the following link:
https://leikozu.net/uploads/files/PAT-N-1109-0519%20MYELOMA%20DIGITAL_RU.pdf
or via the NCCN website and app
https://www.nccn.org/patients/guidelines/content/PDF/myeloma-russian-patient.pdf
Mikhail Savelyevich Laskov, Oncologist, Hematologist and Director of the Dr. Laskov Clinic:
“Multiple myeloma is a fairly common hematological disease, but its considerably difficult to treat. Treatment includes chemotherapy, targeted therapy, supportive therapy, and bone marrow transplantation. The list of analyses and examinations which need to be performed for multiple myeloma diagnosis is extensive. They include PET and MRI scans, complex blood tests, bone marrow aspiration, and genetic analyses. The approach to diagnosis and treatment of multiple myeloma is so complex that even doctors can struggle. So, can you imagine what it is like for patients? I initiated a project to translate the NCCN's cancer and hematology guidelines two years ago and I thank the Leukemia Foundation for their work on this. The guidelines we have translated are the most well written in the world for patients and are produced by the most advanced and widely recognized professional medical association. They allow the patient to keep control over their situation at all times.”
Katerina Pogodina, Managing Director of Janssen Russia and the CIS, General Director of Johnson & Johnson LLC:
“Supporting patients is one of the key areas of our work in Russia. The availability of reliable and credible information about the disease and patient awareness helps build a more constructive and trust-based dialogue with doctors, and therefore potentially improves the disease management process as a whole. We were happy to support our partner's project to translate the guidelines from an advanced international medical association on the treatment of multiple myeloma and we very much hope that this project will benefit a large number of patients and their families as well as the professional community.”
About the Foundation:
The Leukemia Foundation helps adults over the age of 18 with cancers of the blood system such as leukemia, lymphoma, and hematopoiesis depressions. The Foundation offers support for three main programs: bone marrow transplants, targeted assistance, and voluntary donations. To this date, we have already supported more than 250 patients.
About the National Comprehensive Cancer Network:
The National Comprehensive Cancer Network® (NCCN®) is a not-for-profit alliance of leading cancer centers devoted to patient care, research, and education. NCCN is dedicated to improving and facilitating quality, effective, efficient, and accessible cancer care so patients can live better lives. Visit NCCN.org for more information on the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) and other initiatives. Follow NCCN on Facebook @NCCNorg, Instagram @NCCNorg and Twitter @NCCN.
Contact information:
Anna Genina, PR Manager
8903-573-97-14